ILMN · Illumina Inc
Snapshot
50 fields · last close| Market Cap | $40.95B |
| P/E | 50.16 |
| Float | 150.9M |
| Beta | 1.43 |
| Volatility | 35.7% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 67.7 |
| Price | 270.93 |
| Change | −0.09% |
| Prev Close | 271.18 |
| Open | 276.58 |
| Day Low | 267.27 |
| Day High | 276.85 |
| Avg Vol | 3 |
| Avg $ Vol | $765.2M |
| 52W High | 309.35 |
| 52W Low | 88.00 |
| 52W Pos | 82.6% |
| From High | −12.42% |
| From Low | +207.88% |
| Max DD 1Y | — |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | — |
| SMA 50 | — |
| SMA 200 | — |
| RSI (14) | — |
| Vol 30D | — |
| Vol 90D | — |
| 1Y Range | 88–309 |
| Daily bars | — |
| Perf Week | — |
| Perf Month | — |
| Perf Quarter | — |
| Perf Half Y | — |
| Perf Year | — |
| Perf YTD | — |
| Prev Day | −0.09% |
| Clavix | B- |
| Debt / Eq | 0.31 |
| Curr Ratio | 2.08 |
| Int Cover | 11.0× |
| FCF Margin | 21.4% |
| Rev Growth | −0.7% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 15 / 19 |
Clavix risk grade
regraded every trading dayILMN grades B-, 67.7 of 100. Steadiest on Sector Resilience (71), most exposed on Price Stability (50, mixed). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 15 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| ILMN | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.43 | 1.17 |
| Volatilityannualized | 35.7% | 29.3% |
| Max drawdown, past yearworst peak-to-trough fall | — | — |
| Typical daily movemedian absolute daily change | — | — |
| Days beyond ±3%of the last 0 sessions | — | — |
Market sensitivity
| ILMN | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.43 | 1.17 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ILMN | |
|---|---|
| 1 week | — |
| 1 month | — |
| Year to date | — |
| 1 year | — |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ILMN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 3 Aug |
| Average score0 most bearish, 100 most bullish | 57 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 7 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 7 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| ILMN | |
|---|---|
| Revenue growthyear over year | −0.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openOn October 14, 2026, Illumina launched BioInsight Platform, its first unified software environment that brings its analysis tools, AI features, and curated biological data into one place to help researchers work with genomic and multiomic data. The launch includes an updated version of DRAGEN, Illumina's secondary analysis (meaning, the step that turns raw DNA sequencing output into readable genetic data) software, now available across both cloud and standard computing setups.
Illumina filed an 8-K on October 13, 2026, disclosing that on October 8, 2026, it set up a commercial paper program allowing it to issue short-term unsecured debt notes up to $1.0 billion at any time, with three dealers initially involved. No notes have been issued yet, and proceeds would go to general corporate purposes.
Wall Street Zen upgraded its rating on Illumina stock from 'hold' to 'buy' in a research note issued on Sunday.
The article examines whether Illumina's competitive advantage is widening or narrowing, arguing the moat comes from the recurring revenue customers must pay for reagents and flow cells after buying a sequencer. It notes revenue grew 9.40% while earnings fell 11.90% in the most recent quarter, which the article reads as a sign that pricing power on those consumables is weakening.
Illumina released SpliceAI2, an updated genomic AI model for finding disease-relevant genetic variants, particularly those linked to rare diseases. In tests on a rare disease dataset, SpliceAI2 found 17% more relevant variants than other splicing models, and combined with Illumina's other genomic AI tools it identifies twice as many variants with predicted biological impact as before.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| WAT | Waters Corp | B+ | $42.45B | 255.53 | 1.16 | Compare |
| IQV | IQVIA Holdings Inc | B | $42.91B | 31.30 | 1.17 | Compare |
| A | Agilent Technologies Inc | B | $48.38B | 33.59 | 1.25 | Compare |
| MTD | Mettler-toledo International Inc | B+ | $32.02B | 34.92 | 1.20 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $23.90B | 48.13 | 1.15 | Compare |
| RVTY | Revvity Inc | B | $17.30B | 73.02 | 1.09 | Compare |
| MEDP | Medpace Holdings Inc | B | $17.02B | 34.67 | 1.11 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $14.27B | — | 1.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.